Multitask learning-driven identification of novel antitrypanosomal compounds

Future Med Chem. 2023 Aug;15(16):1449-1467. doi: 10.4155/fmc-2023-0074. Epub 2023 Sep 13.

Abstract

Background: Chagas disease and human African trypanosomiasis cause substantial death and morbidity, particularly in low- and middle-income countries, making the need for novel drugs urgent. Methodology & results: Therefore, an explainable multitask pipeline to profile the activity of compounds against three trypanosomes (Trypanosoma brucei brucei, Trypanosoma brucei rhodesiense and Trypanosoma cruzi) were created. These models successfully discovered four new experimental hits (LC-3, LC-4, LC-6 and LC-15). Among them, LC-6 showed promising results, with IC50 values ranging 0.01-0.072 μM and selectivity indices >10,000. Conclusion: These results demonstrate that the multitask protocol offers predictivity and interpretability in the virtual screening of new antitrypanosomal compounds and has the potential to improve hit rates in Chagas and human African trypanosomiasis projects.

Keywords: QSAR; deep learning; low-data regimes; model explainability; neglected tropical diseases; trypanosomatids; virtual screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chagas Disease* / drug therapy
  • Humans
  • Trypanocidal Agents* / pharmacology
  • Trypanosoma brucei brucei*
  • Trypanosoma cruzi*
  • Trypanosomiasis, African* / drug therapy

Substances

  • Trypanocidal Agents